Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Mayo Clinic

387 clinical trials

287 abstracts

12 posters

Poster
Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors
Poster
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Mepolizumab Therapy Improves Most Bothersome Symptoms in Patients With Hypereosinophilic Syndrome (HES)
Poster
Safety and efficacy of pralsetinib in patients with advanced RET fusion–positive non-small cell lung cancer: update from the ARROW trial
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT ‘basket’ trial
Poster
Mepolizumab Therapy Improves Most Bothersome Symptoms in Patients With Hypereosinophilic Syndrome
Poster
Safety and efficacy of pralsetinib in patients with advanced RET fusion–positive non-small cell lung cancer: update from the ARROW trial
Poster
Avapritinib Improved Symptoms and Quality of Life in Patients with Indolent Systemic Mastocytosis in the PIONEER Study
Poster
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC
Clinical trial
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).
Org: Dana-Farber Cancer Institute, Weill Cornell Medicine, Stanford Comprehensive Cancer Institute, University of Colorado Cancer Center, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Org: Mayo Clinic Arizona, Azidus Brasil, Jacksonville, Mayo Clinic, Phoenix Tissue Repair,
Abstract
Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial.
Org: Department of Neurosurgery, Prince of Wales Hospital, Department of Radiation Oncology, Baptist Health South Florida, Perelman School of Medicine, Department of Radiology,
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.
Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.
Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Breast cancer risk associated with missense variants in BRCA2.
Org: Ambry Genetics, Harvard T.H. Chan School of Public Health, Sierra Madre, Abramson Cancer Center, University of Pennsylvania,
Abstract
Second primary breast cancer in young breast cancer survivors.
Org: Harvard School of Public Health, Beth Israel Deaconess Medical Center and Harvard Medical School, Stanford Comprehensive Cancer Institute, Odette Cancer Centre, Beth Israel Deaconess Medical Center,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.
Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.
Org: Mayo Clinic, Northwestern University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Iowa, City of Hope National Medical Center,
Abstract
Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).
Org: MGH Cancer Center, Massachusetts General Hospital, Mayo Clinic, Ludwig Center at Harvard Medical School, Dana-Farber Cancer Institute,
Abstract
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Org: Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UT Southwestern Simmons Comprehensive Cancer Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.
Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.
Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
Vincristine (VCR) pharmacokinetics (PK) in infants dosed using a body surface area (BSA) banded dosing table and in older children dosed based on BSA: A pediatric early phase clinical trial network study (PEPN22P1).
Org: Children's Hospital Colorado, Aurora, CO, Children's Hospital of Philadelphia, Children's Oncology Group Statistics and Data Center, University of Florida, Texas Children's Cancer and Hematology Center, Institute for Clinical and Translational Research, Baylor College of Medicine,
Abstract
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).
Org: Children's Hospital of Philadelphia, Mayo Clinic, Department of Population Health Sciences, Weill Cornell Medicine, Children’s Hospital Los Angeles,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.
Org: Mayo Clinic Department of Pediatric and Adolescent Medicine, Mayo Clinic, Indiana University School of Medicine and Regenstrief Institute, Yale University School of Medicine, National Cancer Institute/National Institutes of Health,
Abstract
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.
Org: Mayo Clinic, University of Minnesota, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology.
Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California, San Francisco, NYU Langone Health, Mayo Clinic,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).
Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.
Org: University of California, San Francisco, Miami Cancer Institute, Baptist Health South Florida, Mayo Clinic, Rush University Medical Center,
Abstract
Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer.
Org: Mayo Clinic, Rochester, MN, AstraZeneca, Gaithersburg, MD,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy.
Org: Mayo Clinic Florida, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
Org: Mayo Clinic, University of California Irvine, UCSF Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Alliance for Clinical Trials in Oncology,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).
Org: UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA, Mayo Clinic, Miami Cancer Institute, Baptist Health South Florida, NW Medical Specialties,
Abstract
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.
Org: Cancer Research @UCC, Brown University - ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Saint Vincent Hospital Cancer Center Green Bay, University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Org: Yale School of Medicine, Mayo Clinic, Oncology Center of Excellence, U.S. Food and Drug Administration, Cancer Outcomes, Public Policy and Effectiveness Research Center,
Abstract
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Org: Brown University/Legorreta Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, University of Kansas Medical Center,
Abstract
SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Org: Mayo Clinic, Indiana University School of Medicine, Regenstrief Institute, Mayo Clinic Florida, National Cancer Institute/National Institutes of Health,
Abstract
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.
Org: University of California, San Francisco Department of Surgery, University of California, San Francisco, Susan G. Komen, UCSF Breast Science Advocacy Core, Mayo Clinic - Department of Surgical Oncology,
Abstract
Social determinants of health and patient reported outcomes in lung cancer survivors.
Org: Mayo Clinic, Department of Pediatric and Adolescent Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Department of Quantitative Health Sciences, Mayo Clinic Arizona,
Abstract
Time-to-diagnosis and peri-diagnostic healthcare utilization between screen- and non-screen detected cancers: Evidence from SEER-Medicare.
Org: Exact Sciences Corporation, Curta, Inc., Curta Inc, Exact Sciences Corp., Mayo Clinic,
Abstract
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic experience.
Org: Mayo Clinic, Rochester, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Mayo Clinic Florida, Jacksonville,
Abstract
Surgical outcomes for non-small cell lung carcinoma by race and surgical facility types in the United States.
Org: Mayo Clinic, Mitchell Cancer Institute, University of South Alabama,
Abstract
A deep learning–enabled workflow to estimate real world progression-free survival in patients with metastatic breast cancer.
Org: nference, nference Labs, Mayo Clinic,
Abstract
Performance of an artificial intelligence/machine learning model designed to identify hospitalized patients with cancer who could benefit from timely specialized palliative care delivery.
Org: Mayo Clinic, University of Michigan Medical School,
Abstract
Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Org: Mayo Clinic, U.S. Food and Drug Administration, Yale University, Fight Colorectal Cancer, Arlington, VA, CancerHacker Lab,
Abstract
Long term impact of COVID-19 pandemic on mammographic breast cancer screening.
Org: Mayo Clinic, Department of Quantitative Health Sciences, Mayo Clinic Arizona, Department of Statistics, Mayo Clinic Scottsdale,
Abstract
Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
Org: Mayo Clinic, NYU Langone Health, H. Lee Moffitt Cancer Center and Research Institute, The University of Texas MD Anderson Cancer Center, University of California Irvine,
Abstract
Colorectal cancer and the heart: Uncovering the beat of racial disparities in MACCE.
Org: Landmark Medical Center, New York Medical College, Department of Oncology, National Taiwan University Hospital, Mayo Clinic,
Abstract
Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond.
Org: Mayo Clinic, Rochester, MN,
Abstract
Barriers to accrual and enrollment in brain tumor trials.
Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA.
Org: Mayo Clinic, Predicine Inc., Predicine, Inc., Department of Neurologic Surgery, Department of Neurology and Hematology-Oncology,
Abstract
PK-PD-efficacy modeling of brigimadlin in MDM2-amplified glioblastoma.
Org: Mayo Clinic, University of Minnesota, Boehringer Ingelheim,
Clinical trial
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2027-08-15
Clinical trial
GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence - A Pilot Study
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Clinical trial
Safety of Intraarterial Infusion of Adipose Tissue-derived Mesenchymal Stromal Cells to Treat Antibody-mediated and Cellular Rejection in Adult Kidney Transplant Recipients (AMSCAR)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Onset of Sensory Blockade in Ultrasound-Guided Ankle Block With Mepivacaine Versus Bupivacaine: A Randomized Non-Inferiority Clinical Trial
Status: , Estimated PCD: 2024-07-01
Clinical trial
AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women
Status: , Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)
Status: Completed, Estimated PCD: 2021-08-10
Clinical trial
Evaluation of Feasibility in the Prophylaxis of Radiation Dermatitis Severity in Cancer Patients
Status: Terminated, Estimated PCD: 2024-01-30
Clinical trial
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Status: Active (not recruiting), Estimated PCD: 2019-02-02
Clinical trial
COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults
Status: , Estimated PCD: 2024-12-01
Clinical trial
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy
Status: Active (not recruiting), Estimated PCD: 2022-12-27
Clinical trial
Niacin Regulation of Regional Adipose Tissue Lipolysis
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Prospective, Randomized Clinical Trial Comparing Analgesic Efficacy of Liposomal Bupivacaine Single-Injection Interscalene Blockade to Continuous Interscalene Blockade for Patients Undergoing Primary Total Shoulder Arthroplasty
Status: Completed, Estimated PCD: 2023-03-18
Clinical trial
Impact of Focused Low-intensity Shockwave Therapy (LiSWT) in Penile Disorders (Peyronie's Disease, Erectile Dysfunction, or Both), With or Without Intralesional Clostridial Collagenase (Xiaflex) Injection, Compared With Radial Shock Wave Therapy or Xiaflex Therapy
Status: Withdrawn, Estimated PCD: 2024-12-01
Abstract
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
Org: Miami Cancer Institute, Baptist Health South Florida, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, CHUM,
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).
Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Org: Division of Hematology, Mayo Clinic, Rochester, MN, Stanford University Medical Center, Palo Alto, CA, University of Kansas Medical Center, Kansas City, KS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Abstract
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.
Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Rochester, MN, USA, University of Rochester, Rochester, NY, Massachusetts General Hospital, Marblehead, MA, Dana-Farber Cancer Institute, Boston, MA, USA,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.
Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Clinical trial
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Status: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
Status: Completed, Estimated PCD: 2023-11-04
Clinical trial
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Status: Recruiting, Estimated PCD: 2024-09-14
Clinical trial
A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.
Status: Active (not recruiting), Estimated PCD: 2050-12-01
Clinical trial
Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA) A Phase II, Prospective, Double-Blind Randomized Trial
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Randomized, Double-blind, Placebo Controlled, Dose Escalation Pilot Study Evaluating the Efficacy of Two Doses of Duloxetine and Amitriptyline in Interstitial Lung Disease-related Cough
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Acupuncture Therapy for COVID-Related Olfactory Loss
Status: Completed, Estimated PCD: 2023-04-21
Clinical trial
Stimulation of Regional Lipolysis and Adipocyte Lipolysis Proteins
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
Status: , Estimated PCD: 2026-07-31
Clinical trial
Phase II Study of FGFR Inhibitor Futibatinib in Combination With Anti-PD-1 Antibody Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma With FGF19 Expression After First Line Therapy
Status: Recruiting, Estimated PCD: 2025-05-06
Clinical trial
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension
Status: , Estimated PCD: 2025-05-01
Clinical trial
Impact of Cystatin-C C-guided Vancomycin Dosing Recommendation on Target Trough Achievement and Clinical Outcomes in Critically Ill Adults
Status: Completed, Estimated PCD: 2015-06-01
Clinical trial
Use of Natural Signals and Ambient Dendritic Cells to Culture-Expand Cancer Targeting T-Cells Directly From Unfractionated Peripheral Blood: A Phase 1 T-Cell Dose Escalation Trial Targeting Relapsed and Refractory MUC1-Expressing Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Reishi Mushroom Extract for Fatigue and/or Arthralgias in Patients With Breast Cancer on Aromatase Inhibitors: A Randomized Phase II MNCCTN Trial
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)
Status: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
Utility of Gallium-68-DOTA-Octreotate PET/CT in the Characterization of Pediatric Neuroendocrine Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Clopidogrel Monotherapy in High Bleeding Risk Patients Undergoing Percutaneous Coronary Interventions: A Safety Assessment, Pilot Study to Reduce Post-Discharge Bleeding
Status: Completed, Estimated PCD: 2023-03-16
Clinical trial
Randomized Phase II Study of Standard Chemotherapy With Docetaxel With or Without Bintrafusp Alfa in Patients With Advanced NSCLC After Progressing on a Combination of Anti-PD-1/PD-L1 Agents and Chemotherapy
Status: Terminated, Estimated PCD: 2023-12-31
Clinical trial
A Phase IV Randomized, Single-Blind Trial of Liposomal Bupivacaine (Exparel®) for Pain Control in Costal Cartilage Harvest
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)
Status: Completed, Estimated PCD: 2023-09-20
Clinical trial
A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence & Patient Reported Symptom Occurrence & Interference w/ Daily Life Comparing Envarsus XR® & Immediate Release Tacrolimus in Adult Renal Transplant Recipients (SIMPLE)
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast Cancer
Status: Completed, Estimated PCD: 2024-01-10
Clinical trial
Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
Status: Active (not recruiting), Estimated PCD: 2027-01-20
Clinical trial
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase IB Trial of Neoadjuvant Multi-Epitope HER2 Peptide Vaccine in Patients With HER2-Expressing DCIS
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression: An Unblinded Phase 1 Safety, Methodological and Exploratory Biomarkers Study.
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Pancreatic Cancer and Peritoneal Metastasis
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Neostigmine and Glycopyrrolate for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial
Status: Completed, Estimated PCD: 2023-07-14
Clinical trial
Efficacy of Peripheral Nerve Blocks for Episodic Migraine Treatment and Prophylaxis
Status: Recruiting, Estimated PCD: 2025-02-01
Abstract
Soluble mesothelin neutralizes mesothelin antibody-based therapies.
Org: Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Abstract
A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA).
Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers.
Org: Mayo Clinic, Guardant Health Inc., Guardant Health, Inc.,
Abstract
Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.
Org: Mayo Clinic, Rochester, MN,
Abstract
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.
Org: Mayo Clinic, Mayo Clinic Department of Oncology,
Abstract
Prognostication of ß-catenin (CTNNB1) in patients with HCC treated with first line immunotherapy.
Org: Mayo Clinic, Mayo Clinic Cancer Center, Alliance Statistics and Data Management Center,
Abstract
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.
Org: Mayo Clinic, Mayo Clinic Florida,
Abstract
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).
Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,
Abstract
Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function.
Org: Mayo Clinic, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
Predictors of symptom scores in myeloproliferative neoplasms: A real-world retrospective cohort study.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Mayo Clinic Arizona,
Abstract
A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma.
Org: Washington University School of Medicine in St. Louis, Mayo Clinic, Washington University in St. Louis, BostonGene, Corp., BostonGene Corporation,
Abstract
SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.
Org: Mayo Clinic Rochester, Rochester, MN, Clarity Pharmaceuticals, XCancer Omaha, Omaha, NE, Washington University in St. Louis, Mayo Clinic,
Abstract
A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis.
Org: Mayo Clinic Rochester, Rochester, MN, Mayo Clinic Arizona, Mayo Clinic Florida, Mayo Clinic Alliance Statistics and Data Center, Mayo Clinic,
Abstract
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Mayo Clinic Rochester, Rochester, MN, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Understanding fellow hematology curriculums: Characterizing perspectives and defining opportunities for improvement.
Org: Mayo Clinic, Rochester, MN,
Abstract
Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC).
Org: Mayo Clinic, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
Org: Bristol Myers Squibb, Mayo Clinic, Lille University Hospital, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
Efficacy and toxicity of BRAF targeted therapy in elderly patients with melanoma.
Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida, Mayo Clinic Arizona,
Abstract
Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation.
Org: Mayo Clinic Florida, Mayo Clinic,
Clinical trial
RECLAIM: A Phase I Safety and Feasibility Trial of REcycled CartiLage Auto/Allo IMplantation for the Treatment and Repair of Focal Knee Cartilage Defects
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Abstract
PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.
Org: TILT Biotherapeutics, Mayo Clinic, Docrates Cancer Center, Cancer Gene Therapy Group, Merck & Co., Inc.,
Abstract
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.
Org: Mayo Clinic, Actuate Therapeutics, Inc., Brown University - Lifespan Cancer Institute, Legorreta Cancer Center, Legorreta Cancer Center at Brown University,
Abstract
Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
Org: Mayo Clinic, University Medical Center Hamburg-Eppendorf, Regeneron Pharmaceuticals, Inc., EVERSANA, Burlington, ON, Canada, Mount Sinai Hospital-Breast Medical Oncology,
Abstract
Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT).
Org: Memorial Sloan Kettering Cancer Center, Seres Therapeutics, University of Chicago, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic,
Abstract
EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Org: A2 Biotherapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic, NYU Langone Health, New York, NY, Washington University in St. Louis,
Clinical trial
Phase Ib Trial of Low-Dose Selinexor (KPT-330) in Combination With Choline Salicylate (CS) for the Treatment of Patients With Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasms, or Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-12-15
Abstract
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.
Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Scottsdale,
Abstract
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,
Abstract
Efficacy and toxicity of KIT targeted therapy in elderly patients with melanoma.
Org: Mayo Clinic, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Mayo Clinic Florida,
Abstract
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
Org: Mayo Clinic, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Department of Hematology and Oncology, Mayo Clinic Florida, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Remote patient monitoring for early detection of immune checkpoint inhibitor therapy-related pneumonitis in high-risk patients: A pilot-feasibility study.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic School of Graduate Medical Education,
Abstract
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.
Org: Evidera, Inc, GRAIL, LLC, a subsidiary of Illumina, Inc., Ontada, Mayo Clinic, Dana-Farber Cancer Institute,
Abstract
Metformin and cytokine release syndrome after immune effector cell therapy.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic Rochester, Rochester, MN,
Abstract
Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502.
Org: Roswell Park Comprehensive Cancer Center, Mayo Clinic, Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,
Abstract
Effect of AURKA targeting on nuclear PD-L1 and the efficacy of immune checkpoint inhibitors in triple-negative breast cancer.
Org: Mayo Clinic, Rochester, MN,
Abstract
Correlation of ctDNA with hematologic ratios (NLR, MLR, PLR, ELR) in predicting disease progression in soft tissue sarcomas among non-Hispanic Whites and Hispanics: Single-center experience.
Org: Creighton University School of Medicine Phoenix Regional Campus, Creighton University Medical Center, Mayo Clinic, Dignity Health Cancer Institute, Dignity Health Cancer Center,
Abstract
Class comparison of BCMA-directed therapies in relapsed multiple myeloma.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Rochester, MN, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Prognostic factors of grade 4 IDH-mutant astrocytoma.
Org: Mayo Clinic, Rochester Regional Health System, MN,
Abstract
First relapse in patients with multiple myeloma: Outcomes and predictors.
Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic Rochester, Rochester, MN, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Abstract
Association of human interpretable features derived from pancreatic ductal adenocarcinoma pathology slides with disease-free survival.
Org: Mayo Clinic, Rochester, MN,
Abstract
Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.
Org: Mayo Clinic, Rochester, MN, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Indianapolis, IN, Scottsdale, AZ,
Abstract
PTPN11 variants in chronic myelomonocytic leukemia: Phenotypic and prognostic correlates.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Clinical trial
Imaging the Migraine Brain Pre- and Post-Erenumab: an MRI Study to Identify Functional and Structural Changes That Correlate With Patient Improvement
Status: Completed, Estimated PCD: 2022-06-30
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
Org: Next Oncology Virginia and Virginia Cancer Specialists, Sir Charles Gairdner Hospital, Calvary Mater Hospital, University of Vermont Cancer Center, Stephenson Cancer Center,
Abstract
The effect of distance reiki on patient reported quality of life, correlated with changes in immune repertoires among patients with multiple myeloma: A pilot study.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN,
Abstract
Quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma (TENDMM): A systematic review and meta-analysis.
Org: Mayo Clinic, Phoenix Tissue Repair, Azidus Brasil, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Phoenix, AZ,
Clinical trial
Phase II Trial of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (HP) Plus Enzalutamide for the Treatment of Selected Patients With Metastatic Castration-Resistant Prostate Cancer (TraPPer)
Status: Recruiting, Estimated PCD: 2025-10-01
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
Navigating the intersection: Exploring racial disparities in major cardiovascular and cerebrovascular events among patients with hepatocellular carcinoma.
Org: Landmark Medical Center, Woonsocket, River 3 Renal, New York Medical College - Saint Michael's Medical Center, Valhalla,
Abstract
Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701.
Org: Massachusetts General Hospital, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,
Clinical trial
Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction
Status: , Estimated PCD: 2024-12-01
Clinical trial
A Phase II Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effects of Ketamine Infusions in Clinically Depressed ICU Patients
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501
Status: Recruiting, Estimated PCD: 2027-01-15
Abstract
Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants.
Org: Department of Laboratory Medicine and Pathology, University of Washington, Mayo Clinic, Rochester Regional Health System, MN, Ambry Genetics,
Clinical trial
Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
Status: , Estimated PCD: 2025-12-01
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.
Org: Dana-Farber Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Massachusetts General Hospital, Stanford Comprehensive Cancer Institute,
Abstract
Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.
Org: Yale New Haven Hospital, Yale Cancer Center, Stanford Hospital and Clinics, Campus Bio Medico University of Rome, MedStar Health/Georgetown University Hospital,
Abstract
Counting coins and cardiovascular catastrophes: The income–pancreas connection.
Org: Landmark Medical Center, New York Medical College - Saint Michael's Medical Center, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Mayo Clinic, Sheikh Shakhbout Medical City in Partnership With Mayo Clinic,
Clinical trial
Phase 1/2 Trial of Selinexor in Combination With Pomalidomide and Dexamethasone ± Carfilzomib for Patients With Proteasome-Inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma (SCOPE)
Status: Recruiting, Estimated PCD: 2025-03-04
Abstract
Assessing gender disparities in oncology: Less talk, more action.
Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California Irvine, Mayo Clinic, Dana-Farber Cancer Institute,
Clinical trial
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2019-11-14
Clinical trial
Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU
Status: Recruiting, Estimated PCD: 2025-12-20
Clinical trial
A Phase 2 Open-label Trial Evaluating the Efficacy and Safety of Daratumumab in Treatment of Patients With Active Lupus Nephritis
Status: Recruiting, Estimated PCD: 2026-07-01
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).
Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Clinical trial
Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Treatment of Headache With Occipital Nerve Blocks: Comparison Trial of Anesthetic With or Without Dexamethasone
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Cellkine: Phase II Study Evaluating Safety and Preliminary Efficacy of Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells in Subjects With Painful Lumbar Facet Joint Arthropathies
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Status: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Metformin Effect on Brain Function in Insulin Resistant Elderly People
Status: Completed, Estimated PCD: 2023-04-05
Clinical trial
Paravertebral Block vs no Block in Open Pancreaticoduodenectomy: Prospective Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase 1 Study of the Administration of Ipilimumab Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE With Nivolumab Administered IV in Patients With Metastatic Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Enhancing Adaptations to Exercise
Status: Completed, Estimated PCD: 2021-12-31
Clinical trial
Development and Validation of Innovative Hybrid Molecular Imaging, 68Ga-PSMA-Dual Contrast PET/MRI and 68Ga-PSMA PET/CT, to Transform the Care of Patients With Hepatocellular Carcinoma
Status: Completed, Estimated PCD: 2023-11-02
Clinical trial
A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients
Status: Active (not recruiting), Estimated PCD: 2021-03-26
Clinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Tadalafil Versus Placebo in Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology (TRIUMPH Trial)
Status: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis
Status: Completed, Estimated PCD: 2020-08-01
Clinical trial
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Randomized-Controlled Trial Comparing Long-acting and Short-acting Local Anesthetics at the Time of Penile Prosthesis Placement
Status: Completed, Estimated PCD: 2024-01-07
Clinical trial
Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders
Status: , Estimated PCD: 2050-11-01
Clinical trial
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Status: Completed, Estimated PCD: 2018-10-26
Clinical trial
Insulin Regulation of Regional Lipolysis
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Phase II Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Patients With Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable With Ring Sideroblasts (MDS/MPN-U With RS)
Status: Terminated, Estimated PCD: 2023-04-17
Clinical trial
Hot Flashes and Neurovascular Function in Women
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas
Status: Active (not recruiting), Estimated PCD: 2019-07-01
Clinical trial
Preoperative Radiosurgery in High Grade Glioma: A Phase I/IIA Clinical Trial: The NeoGlioma Study
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
CELLTOP Part II: A Phase II Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Letrozole in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial
Status: Terminated, Estimated PCD: 2021-03-26
Clinical trial
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Status: Active (not recruiting), Estimated PCD: 2027-03-17
Clinical trial
A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD)
Status: Active (not recruiting), Estimated PCD: 2023-11-21
Clinical trial
Impact of Individualized Estrogen Therapy on Cardiovascular Disease Risk Parameters in Young Women After Bilateral Oophorectomy: A Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-08-28
Clinical trial
Impact of Ketamine Versus Propofol for Anesthetic Induction on Acute Kidney Injury and Renal Biomarkers in Cardiac Surgery
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
INTERogating Cancer for Etiology, Prevention and Therapy Navigation (INTERCEPTioN)
Status: Recruiting, Estimated PCD: 2033-09-01
Clinical trial
Aerosolized Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim) in Combination With Anti-PD1 Therapy for the Treatment of Metastatic Melanoma to the Lung
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Status: Completed, Estimated PCD: 2012-08-01
Clinical trial
A Phase Ib, Double-Blind, Placebo-Controlled, Single-site Trial to Determine the Safety and Efficacy of a Novel Renal-Specific Peptide, ANX-042, in Enhancing GFR Without Significant Hypotension in Human Cardiorenal Syndrome (CRS): ANX-042 Aim #1
Status: , Estimated PCD: 2024-12-01
Clinical trial
The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation
Status: Completed, Estimated PCD: 2021-02-28
Clinical trial
Phase 1 Trial of Safety and Preliminary Efficacy of Segmental Ablative Radioembolization in Combination With Tremelimumab Plus Durvalumab (MEDI4736) in Patients With Unresectable, or Oligo-Metastatic Cholangiocarcinoma Who Are Not Candidates for Curative Therapy (RAIDEN Trial)
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD
Status: Recruiting, Estimated PCD: 2030-06-01
Clinical trial
Sciatic Block in Contralateral Limb for Treatment of Refractory Phantom and Residual Limb Pain; a Double-Blind Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy)
Status: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Pilot Feasibility Trial of Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Rose Geranium in Sesame Oil Nasal Spray as an Agent to Improve Symptoms of Nasal Vestibulitis: A Phase III Double Blinded Randomized Controlled Trial
Status: Completed, Estimated PCD: 2022-12-15
Clinical trial
Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study Evaluating Acetazolamide Efficacy in Ataxia in PMM2-CDG
Status: Terminated, Estimated PCD: 2024-01-24
Clinical trial
A Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Safety and Feasibility of Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Stereotactic Accelerated Radiotherapy in GlioblastomA (SAGA)
Status: Recruiting, Estimated PCD: 2027-03-02
Clinical trial
ASCLEPIOS Autologous Stem CelL Expansion and Prospective Injection for Osteoarthritic Hip Symptoms
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Vaccine Effectiveness and Seroconversion to 23 Valent Pneumococcal Polysaccharide Vaccination in Children With Type 1 Diabetes
Status: Completed, Estimated PCD: 2023-01-20
Clinical trial
REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)
Status: Recruiting, Estimated PCD: 2027-11-20
Clinical trial
Double Blind, Single-Center, Randomized, Within Subject Placebo, Phase I Study Evaluating the Effects of Novel Topical Gel in Prevention of Hypertrophic Scar Formation
Status: Terminated, Estimated PCD: 2020-02-26
Clinical trial
The Efficacy of Landmark-guided Percutaneous Sphenopalatine Ganglion Block on Self-reported Headache Pain Secondary to Aneurysmal Subarachnoid Hemorrhage: A Feasibility Study
Status: Completed, Estimated PCD: 2024-04-08
Clinical trial
Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Status: , Estimated PCD: 2024-08-31
Clinical trial
IL-4 & Insulin Resistance in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2024-02-23
Clinical trial
Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Status: Recruiting, Estimated PCD: 2024-09-04
Clinical trial
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Status: Completed, Estimated PCD: 2024-03-18
Clinical trial
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia in Fetuses With Intrauterine Renal Failure or Severe Renal Anomalies- a Feasibility Study
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Double-Blinded, Placebo-Controlled Trial to Explore the Anti-Androgen, Ketoconazole, for Treating Patients With an Ongoing Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash
Status: Active (not recruiting), Estimated PCD: 2024-06-15
Clinical trial
Contrast-enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema (CASTLE) Study
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Status: Completed, Estimated PCD: 2020-10-30
Clinical trial
A Pilot Study: Evaluating the Safety and Feasibility of Using Autologous Adipose-Derived Stromal Cells From Stromal Vascular Fraction (SVF) on Adults With Pressure Ulcers or Diabetic Foot Ulcers
Status: , Estimated PCD: 2024-12-01
Clinical trial
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria: An Open-label, Single-arm, Exploratory Study
Status: Active (not recruiting), Estimated PCD: 2023-11-15
Clinical trial
A Phase II Trial of Hypofractionated Radiation Therapy for Prostate Cancer With High Risk Features After Radical Prostatectomy
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
Phase 2 Randomized Trial of Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-07-02
Clinical trial
Efficacy of Self-management of Sedative Therapy by Ventilated ICU Patients
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Radiation Therapy, Plasma Exchange, and Immunotherapy in Melanoma
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function
Status: Completed, Estimated PCD: 2013-06-13
Clinical trial
Expansion Cohort Study of Disulfiram and Chemotherapy in Pancreas Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase 1 Study of the Administration of STI-3031 (Anti-PDL1) Intra-Lymphatically Using the Sofusa® DoseConnect™ DEVICE in Patients With In-Transit Melanoma (Sofusa-2)
Status: Active (not recruiting), Estimated PCD: 2026-01-01
Clinical trial
A Pilot Study Evaluating the Use of Autologous Platelet-rich Plasma (PRP) for the Treatment of Erectile Dysfunction
Status: Completed, Estimated PCD: 2023-10-23
Clinical trial
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents
Status: , Estimated PCD: 2025-04-01
Clinical trial
Optimizing Outcomes of Patients With Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-07
Clinical trial
Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Insulin Regulation of Lipolysis and Lipolysis Proteins
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Enfortumab Vedotin Treatment for Metastatic Squamous Cell Carcinoma of the Penis
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Pre-Operative and Post-Operative Paravertebral Block on Patients With Thoracic Outlet Syndrome.
Status: , Estimated PCD: 2024-08-01
Clinical trial
Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Minority-Inclusive Imaging Biomarker-Based End of Therapy Trial for 177Lu-PSMA-617, a Randomized De-Escalation Theranostic Trial for Metastatic Castrate Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2029-12-31
Clinical trial
COordinated Nivolumab and IntraperiToneal IL-2 for Gastric CanceR With PeritOneaL Metastasis (CONTROL) Phase 1b Pilot Study
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Cluster Headache Treatment With Rimegepant-Open Label Pilot Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-05-07
Clinical trial
A Phase 2 Pilot Window of Opportunity Study Turkey Tail Mushrooms (TTM) (Trametes Versicolor) in Post-Menopausal Women With HER2 (-) ER (+) Breast Cancer Planning to Undergo Surgical Therapy
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Clinical trial
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol (TACTIC) Trial
Status: Recruiting, Estimated PCD: 2028-02-28
Clinical trial
Mayo Clinic Health System-wide Neurological, Vascular and Neurovascular Events With SARS-CoV-2- Part II
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Identification of the Optimal Analgesic Dose of Intrathecal Hydromorphone for Pediatric Patients Undergoing Posterior Spine Surgery for Idiopathic Scoliosis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers
Status: Recruiting, Estimated PCD: 2025-11-15
Clinical trial
A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors
Status: Active (not recruiting), Estimated PCD: 2013-11-01
Clinical trial
FRαDCs Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer
Status: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress
Status: Active (not recruiting), Estimated PCD: 2013-05-11
Clinical trial
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Status: Not yet recruiting, Estimated PCD: 2027-02-15
Clinical trial
AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults
Status: , Estimated PCD: 2024-06-01
Clinical trial
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple Myeloma
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
Phase II Trial for Evaluation of Alternate Doses and Dosing Schedules of Belantamab Mafodotin in Triple-Class Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
Impact of Concurrent Low Intensity Shockwave Therapy on Clinical Outcomes With Collagenase Clostridium Histolyticum in Peyronie's Disease: A Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Individualizing Corticosteroid Use in Pneumonia
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study
Status: Completed, Estimated PCD: 2022-11-17
Clinical trial
Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
Status: Recruiting, Estimated PCD: 2025-06-29
Clinical trial
An Open-Label Phase 1 Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2022-09-21
Clinical trial
DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer
Status: Active (not recruiting), Estimated PCD: 2022-08-20
Clinical trial
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase II Study of a Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab (MEDI4736) in Patients With Richter Transformation From Chronic Lymphocytic Leukemia (CLL)
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
Fenofibrate to Prevent Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation (FICsDCD)
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Intravital Microscopy (IVM) in Human Solid Tumors
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Three-Arm, Double-Blinded, Randomized Controlled Trial Comparing the Efficacy of Adductor Canal Pain Catheters Following Total Knee Arthroplasty
Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
Phase II Trial of Standard Platinum Doublet Chemotherapy + Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease
Status: Active (not recruiting), Estimated PCD: 2019-07-31
Clinical trial
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-21
Clinical trial
Utility of 18F-DOPA PET/MRI Metrics as a Biomarker for Treatment Response Assessment in Sarcoma Patients: A Pilot Study
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Randomized Control Trial Comparing Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
Status: , Estimated PCD: 2025-12-31
Clinical trial
A Phase I Study of Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-11-22
Clinical trial
Phase 0/I Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2026-05-15
Clinical trial
A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
68Ga-PSMA-11 PET/CT for Screening Prior to 177Lu-PSMA-617 Therapy
Status: Completed, Estimated PCD: 2023-12-31
Clinical trial
DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy
Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Status: Terminated, Estimated PCD: 2024-05-07
Clinical trial
Prospective, Randomized, Double-blinded, Split-face Study Comparing Efficacy of Lidocaine 2.5%/Prilocaine 2.5% Cream Under Occlusion, and Lidocaine 23% /Tetracaine 7% Ointment for Anesthesia Prior to 1927nm Fractional Laser Treatment
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
DaTSCAN Imaging in Aging and Neurodegenerative Disease
Status: , Estimated PCD: 2025-12-01
Clinical trial
Phase 1/2 Trial of Indomethacin in Chronic Pancreatitis (The PAIR Trial)
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
A Phase II Study of Ibrutinib as Prophylaxis for Chronic Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Clinical trial
Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies
Status: Recruiting, Estimated PCD: 2025-06-03
Clinical trial
Statins and CPAP in Adipose Tissue: A Randomized Clinical Trial in Obstructive Sleep Apnea
Status: Completed, Estimated PCD: 2023-12-12
Clinical trial
Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT Using Cyclotron-Produced 68Ga
Status: Recruiting, Estimated PCD: 2025-01-10
Clinical trial
Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPα-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patients - A Confirmatory Phase III MNCCTN Trial
Status: Withdrawn, Estimated PCD: 2023-12-29
Clinical trial
A Phase I Single Site Open Label Study of Intra-arterial Delivery of Mesenchymal Stem Cells for Luminal Ulcerative Colitis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Practical Anemia Bundle for SusTained Blood Recovery (PABST-BR) Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty: A Single Institution, Single-blinded, Randomized Clinical Trial
Status: , Estimated PCD: 2025-01-01
Clinical trial
Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2040-12-31
Clinical trial
Pilot Study to Test the Safety and Efficacy of the Combination of Imiquimod and Pembrolizumab for the Treatment of Metastatic Melanoma
Status: Active (not recruiting), Estimated PCD: 2021-10-01
Clinical trial
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Pilot Study of Varenicline for Tobacco Dependence Treatment in Recovering Alcoholic Smokers: the Clinical Trial
Status: Completed, Estimated PCD: 2008-09-01
Clinical trial
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast Cancer
Status: Completed, Estimated PCD: 2022-12-12
Clinical trial
Open Label Single Center Trial Evaluating the Efficacy and Safety of Diazepam in GAD65 Associated Epilepsy
Status: , Estimated PCD: 2024-12-01
Clinical trial
Phase II Study of Short Course Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA-PET/MRI for Elderly Patients With Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2022-01-10
Clinical trial
Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Status: Recruiting, Estimated PCD: 2029-05-31
Clinical trial
A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-01-06
Clinical trial
The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study
Status: Active (not recruiting), Estimated PCD: 2014-05-12
Clinical trial
Use of Midodrine in Septic Shock Patients: Phase II Randomized Clinical Meta-trial
Status: Not yet recruiting, Estimated PCD: 2029-05-30
Clinical trial
Phase 1 Pilot Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Symptoms in Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2019-11-06
Clinical trial
A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast Cancer
Status: Terminated, Estimated PCD: 2023-01-11
Clinical trial
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome
Status: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
Resistance Training and 1,25 (OH)2D3 Administration to Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
Status: Completed, Estimated PCD: 2020-05-21
Clinical trial
Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy
Status: Recruiting, Estimated PCD: 2030-01-22
Clinical trial
Developing an Approach to Perturbation of Human Small Intestinal and Colonic Permeability in Healthy Participants
Status: Recruiting, Estimated PCD: 2024-01-23
Clinical trial
Phase II Study of P1101 in Early Myelofibrosis
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Efficacy of Intranasal Povidone Iodine Swab Versus Oral Antibiotic Prophylaxis to Prevent Surgical Site Infections in Patients Undergoing Mohs Micrographic Surgery
Status: Not yet recruiting, Estimated PCD: 2029-05-01
Clinical trial
A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients After Radiation Therapy for Central Nervous System Tumors
Status: Active (not recruiting), Estimated PCD: 2022-09-15
Clinical trial
Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-07-24
Clinical trial
Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Status: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
A Phase II Study of Daratumumab and Ibrutinib for Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)
Status: Active (not recruiting), Estimated PCD: 2026-02-28
Clinical trial
A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides
Status: Active (not recruiting), Estimated PCD: 2024-10-11
Clinical trial
Stellate Ganglion Blockade for the Prevention of Atrial Fibrillation After Cardiac Surgery: A Randomized Placebo-Controlled Trial
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
GEMINI: An Open-Label, Single-Arm, Phase II Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
Status: Terminated, Estimated PCD: 2023-02-02
Clinical trial
Investigation of the Effects of Opioid Exposure on the Ability of the Diaphragm Muscle to Generate Higher Force Behaviors
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
The Effect of Oral Kavalactones on Cortisol, Measures of Burnout, and Motivation in Nurses
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2022-05-19
Clinical trial
Microscopic Fluorescence-guided Vestibular Schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Status: Completed, Estimated PCD: 2022-05-25
Clinical trial
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Treatment of Established Chemotherapy-Induced Neuropathy With Fingolimod: A Pilot Trial
Status: Completed, Estimated PCD: 2020-12-10
Clinical trial
Spasmodic Dysphonia Pain Study
Status: Completed, Estimated PCD: 2023-07-01
Clinical trial
Prevention of Paclitaxel-Associated Neuropathy With Fingolimod: a Pilot Trial
Status: Completed, Estimated PCD: 2020-06-05
Clinical trial
Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma, Advanced Solid Tumors With Liver Predominant Locally Advanced/Metastatic Disease or Subcutaneous/Cutaneous Lesions
Status: Active (not recruiting), Estimated PCD: 2019-04-19
Clinical trial
Phase 2 Study of MRD Guided, FIxed DuRation TherApy for Previously Untreated Chronic Lymphocytic LeukEmia With Pirtobrutinib and Venetoclax (MIRACLE)
Status: Recruiting, Estimated PCD: 2024-07-19
Clinical trial
Ketamine Infusion for Treatment of Chronic Neuropathic Pain in Traumatic Brachial Plexus Injuries, a Prospective Randomized Control Study
Status: , Estimated PCD: 2024-12-01
Clinical trial
Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-27
Clinical trial
Comprehensive O2 Transfer Analysis From the Lung to Mitochondria of Inhaled Treprostinil in Interstitial Lung Disease Pulmonary Hypertension
Status: , Estimated PCD: 2024-06-01
Clinical trial
A Single-Center Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Study to Assess Effectiveness and Tolerability of Zavegepant as an Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications.
Status: Not yet recruiting, Estimated PCD: 2027-03-01
Clinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2016-11-16
Clinical trial
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Community Study
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2015-11-21
Clinical trial
A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Multi-center Open-label Trial Evaluating the Efficacy and Safety of Daratumumab SC in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID)
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Status: Active (not recruiting), Estimated PCD: 2024-12-21
Clinical trial
Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
Status: , Estimated PCD: 2025-06-01
Clinical trial
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal/Gastroesophageal Junction Adenocarcinoma (PHOX)
Status: Recruiting, Estimated PCD: 2026-05-30
Clinical trial
Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) Relapsed/Refractory or Intolerant to Available Therapies
Status: Recruiting, Estimated PCD: 2026-12-29
Clinical trial
Targeted Prevention of Postpartum-Related Breast Cancer
Status: Recruiting, Estimated PCD: 2026-01-30
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
Status: , Estimated PCD: 2024-08-01
Clinical trial
The Acute Effect of Inflammatory Markers of Atherosclerotic Plaque in Humans
Status: Completed, Estimated PCD: 2006-03-01
Clinical trial
Phase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) in t(11;14) Multiple Myeloma
Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users
Status: Completed, Estimated PCD: 2009-04-01
Clinical trial
Exploratory Study of the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
Status: Completed, Estimated PCD: 2023-02-23
Clinical trial
Advanced MR and PET Imaging in Inflammatory Demyelinating Diseases of the Central Nervous System
Status: , Estimated PCD: 2025-05-01
Clinical trial
68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance: A Study to Determine if a Polygenic Risk Score Influences the Decision Making Options Amongst High Risk Women (GENRE 2)
Status: , Estimated PCD: 2029-12-15
Clinical trial
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Status: , Estimated PCD: 2025-04-01
Clinical trial
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Recurrent Glioblastoma
Status: Completed, Estimated PCD: 2021-06-02
Clinical trial
Erector Spinae Plane Block for Rib Fractures: A Pilot Study
Status: Completed, Estimated PCD: 2022-08-22
Clinical trial
Effect of Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults With Heart Failure With Preserved Ejection Fraction: A Randomized Pilot and Proof-of-Concept Study
Status: Completed, Estimated PCD: 2023-08-25
Clinical trial
A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma
Status: Terminated, Estimated PCD: 2023-04-30
Clinical trial
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract Cancers
Status: Completed, Estimated PCD: 2021-08-13
Clinical trial
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis: A Randomized, Controlled Trial
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot
Status: Completed, Estimated PCD: 2021-05-24
Clinical trial
Effects of Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
Status: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Phase II Clinical Trial of Durvalumab (MEDI4736) and Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Completed, Estimated PCD: 2016-10-20
Clinical trial
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Effect of Delayed-Release Bile Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes Mellitus
Status: Completed, Estimated PCD: 2017-10-18
Clinical trial
Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2021-01-31
Clinical trial
CellKine: Phase I Study Evaluating the Safety and Feasibility of Allogeneic, Culture-Expanded Bone Marrow-Derived Mesenchymal Stem Cells in Subjects With Painful Lumbar Facet Joint Arthropathy
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Effects of Neprilysin Inhibition With ARNI (LCZ 696) on the Cardiorenal and Humoral Response to Acute Saline Volume Expansion in DM With and Without PDD
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia
Status: , Estimated PCD: 2024-06-01
Clinical trial
LS1681: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma
Status: Completed, Estimated PCD: 2023-05-16
Clinical trial
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplant Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple Myeloma
Status: Completed, Estimated PCD: 2021-04-13
Clinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Renal Microvessel Imaging for Characterization of Chronic Kidney Disease
Status: , Estimated PCD: 2028-04-01
Clinical trial
Optical and Biochemical Biomarkers in Early Pancreatic Cancer Significance: A Prospective Study
Status: Completed, Estimated PCD: 2022-03-10
Clinical trial
Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas
Status: Active (not recruiting), Estimated PCD: 2019-10-25
Clinical trial
Risk Stratified De-Escalated De-Intensified Treatment for High Risk Prostate Cancer Patients Based on Pathologic Criteria, Genetic Score, and Biologic Imaging
Status: Recruiting, Estimated PCD: 2027-04-22
Clinical trial
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Effect of Ileocolic-released Conjugated Bile Acid on Satiety, Entero-Endocrine Cell Function, and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype
Status: , Estimated PCD: 2026-05-01
Clinical trial
Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Wound Infiltration With Liposomal Bupivacaine With or Without Intrathecal Analgesia in Laparotomy for Gynecological Malignancy: A Randomized Controlled Trial
Status: Completed, Estimated PCD: 2023-05-08
Clinical trial
Restoring Sensitivity to Immunotherapy Post Failure to the Pacific Regimen: A Pilot Study of Combined Durvalumab (MEDI 4736) and Grid Therapy for Non-Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Tau PET Imaging in African Americans
Status: , Estimated PCD: 2025-05-01
Clinical trial
A Placebo Controlled Study of Colesevelam in Fecal Incontinence
Status: Completed, Estimated PCD: 2022-04-14
Clinical trial
Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors
Status: Completed, Estimated PCD: 2018-07-13
Clinical trial
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression
Status: Completed, Estimated PCD: 2017-07-31
Clinical trial
Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer
Status: Not yet recruiting, Estimated PCD: 2029-07-04
Clinical trial
Transcriptomic Signatures of Influenza Vaccine Responses
Status: Completed, Estimated PCD: 2019-01-02
Clinical trial
A Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients With Connective Tissue Disorders
Status: Completed, Estimated PCD: 2021-07-27
Clinical trial
AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial
Status: Withdrawn, Estimated PCD: 2023-04-18
Clinical trial
Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers
Status: Completed, Estimated PCD: 2018-11-30
Clinical trial
Manipulation Under Anesthesia (MUA) to Treat Postoperative Stiffness After Total Knee Arthroplasty: A Multicenter Randomized Clinical Trial
Status: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study for High-Dose Hydroxocobalamin (Vitamin B12A) for Vasopressor Refractory Hypotension Following Cardiopulmonary Bypass
Status: Terminated, Estimated PCD: 2022-04-01
Clinical trial
Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker.
Status: Completed, Estimated PCD: 2022-06-13
Clinical trial
Phase III Study of Ginseng for Cancer Related Fatigue
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer
Status: Recruiting, Estimated PCD: 2027-08-31
Clinical trial
Engineering Gut Microbiome to Target Cancer-Immune Microenvironment in Breast and Lung Cancer
Status: Completed, Estimated PCD: 2023-03-08
Clinical trial
Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis
Status: Completed, Estimated PCD: 2015-04-01
Clinical trial
COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta
Status: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement in Low Energy Hip Fracture Patients?
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial
Status: Completed, Estimated PCD: 2021-10-25
Clinical trial
Intra-arterially Delivered Autologous Mesenchymal Stem/Stromal Cell Therapy in Patients With Diabetic Kidney Disease: A Phase I Study
Status: Terminated, Estimated PCD: 2020-08-04
Clinical trial
A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension
Status: Withdrawn, Estimated PCD: 2022-12-30
Clinical trial
Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus
Status: , Estimated PCD: 2024-07-01
Clinical trial
Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients
Status: Terminated, Estimated PCD: 2022-10-18
Clinical trial
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
Status: Completed, Estimated PCD: 2018-02-01
Clinical trial
Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure
Status: , Estimated PCD: 2007-01-01
Clinical trial
A Phase II, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy of BASIS™ (Nicotinamide Riboside and Pterostilbene) Treatment for Kidney Protection in Patients Treated by Complex Aortic Aneurysm Repair and Aortic Arch Reconstruction
Status: Completed, Estimated PCD: 2024-03-14
Clinical trial
Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial
Status: Completed, Estimated PCD: 2022-05-26
Clinical trial
Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).
Status: Active (not recruiting), Estimated PCD: 2050-12-01
Clinical trial
MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
Status: Completed, Estimated PCD: 2020-06-16
Clinical trial
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized Study Comparing Intravenous (IV) Acetaminophen to Usual Care for Pain Management for Small Bowel Obstruction - Feasibility Study
Status: , Estimated PCD: 2024-12-01
Clinical trial
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2019-09-18
Clinical trial
Effect of GLP-1 Receptor Agonism on Weight and Caloric Intake in Subjects After Sleeve Gastrectomy
Status: Active (not recruiting), Estimated PCD: 2023-10-04
Clinical trial
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy: Clinical Course and Convalescent Plasma Therapy
Status: Completed, Estimated PCD: 2023-01-15
Clinical trial
A Pilot Study: Evaluating the Safety and Feasibility of Using Autologous Adipose-Derived Stromal Vascular Fraction (SVF) for the Treatment of Aerodigestive & Enterocutaneous Fistulae in Adults
Status: Withdrawn, Estimated PCD: 2027-02-01
Clinical trial
Pilot Study for the Use of Shortened Preemptive Therapy With Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney, Heart, Lung and/or Pancreas) of Hepatitis C Viremic Donors
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection
Status: Completed, Estimated PCD: 2023-04-30
Clinical trial
Mepolizumab for the Treatment of Eosinophilic Fasciitis; An Open-Label, Single-Arm, Exploration Study
Status: Withdrawn, Estimated PCD: 2025-12-01
Clinical trial
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Status: Completed, Estimated PCD: 2022-04-11
Clinical trial
Erenumab For Treatment of Hemicrania Continua
Status: Terminated, Estimated PCD: 2022-04-06
Clinical trial
Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP), Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis: A Pilot Study
Status: , Estimated PCD: 2024-12-31
Clinical trial
Intrathecal Opioids for Pain Control After Colorectal Resection: Determining the Optimal Dose
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Randomized, Controlled, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Intravenous Iron Sucrose in Patients With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)
Status: Withdrawn, Estimated PCD: 2023-05-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Impact of Low Sodium Oxybate on Total Sleep Time in Patients With Idiopathic Hypersomnia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Can Loco-regional Anesthesia With Liposomal Bupivacaine Reduce Intra- and Post-operative Narcotic Use in Patients Undergoing Lower Extremity Revascularization? A Prospective, Triple Blinded, Randomized Trial.
Status: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
Postoperative Pain Control After Enucleation or Evisceration, a Double-Masked Randomized Controlled Trial of Standard Versus Slow-release Bupivacaine
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Feasibility of Treatment for Vaping Cessation
Status: Withdrawn, Estimated PCD: 2023-02-01
Clinical trial
Dynamic Positron Emission Tomography Imaging With 11C-ER176 to Delineate Macrophage Activation in Diabetic Gastroparesis
Status: Completed, Estimated PCD: 2022-03-31
Clinical trial
Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride for Postoperative Analgesia After Breast Reduction Surgery: A Prospective, Single Blind, Non-randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer
Status: Withdrawn, Estimated PCD: 2022-01-01
Clinical trial
The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery
Status: Terminated, Estimated PCD: 2019-11-21
Clinical trial
Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine
Status: Terminated, Estimated PCD: 2018-02-07
Clinical trial
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Status: Completed, Estimated PCD: 2023-04-24
Clinical trial
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Myocardial 123I-MIBG Scintigraphy in Aging and Neurodegenerative Disease
Status: , Estimated PCD: 2025-09-01
Clinical trial
Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
Status: Terminated, Estimated PCD: 2021-06-29
Abstract
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
Org: Mayo Clinic, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Rochester Medical Center Department of Medical Oncology, Loyola University Medical Center, Vanderbilt University Medical Center,
Abstract
NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
Org: Mayo Clinic, Alliance Statistics and Data Center, University of California Irvine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Virginia Health System,
Abstract
Association of Medicaid expansion with treatment receipt, delays in treatment initiation, and survival among young adult women with breast cancer.
Org: American Cancer Society, Mayo Clinic, Emory University School of Medicine,
Abstract
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Org: Mayo Clinic, Dana-Farber Cancer Institute, Mayo Clinic Department of Digital Health, Dow Medical College, Karachi, Pakistan, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
Utilizing predictive modeling to identify patients at high-risk of death from immune checkpoint inhibitor therapy-related pneumonitis.
Org: Mayo Clinic, Rochester,MN,
Abstract
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
Org: Dana-Farber Cancer Institute, Mayo Clinic, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, National Cancer Institute, Vilnius, Lithuania,
Abstract
Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
Org: University of Texas MD Anderson Cancer Center, Cleveland Clinic Foundation, St. Joseph Heritage Health, Ohio State University Wexner Medical Center, Mayo Clinic,
Abstract
Decreasing the burden of febrile neutropenia through dynamic remote patient monitoring: The DEFeNDER program.
Org: Mayo Clinic, Department of Quantitative Science Research, Mayo Hosp, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer.
Org: Mayo Clinic, University Hospitals Gasthuisberg Leuven, KU Leuven, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology (VHIO), Barcelona,
Abstract
Treatment patterns for extramedullary multiple myeloma and outcomes with CAR-T therapy and bispecific antibodies.
Org: Mayo Clinic, Mayo Clinic (Rochester, MN), Mayo Clinic Department of Pediatric and Adolescent Medicine, Division of Hematology, Mayo Clinic, Rochester, MN,
Abstract
Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
Org: Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, UT Southwestern Medical Center, Medical University of South Carolina Hollings Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Stanford University School of Medicine,
Abstract
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Org: Memorial Sloan Kettering Cancer Center, Guy’s and St Thomas’ NHS Trust, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia "Seràgnoli", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,
Abstract
Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Org: Dana-Farber Cancer Institute, Gilead, Stanford University School of Medicine, City of Hope National Medical Center, The University of Kansas Medical Center,
Abstract
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
Org: Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCI Health,
Abstract
Hematology/oncology program director perspectives on recruitment and inclusion of a diverse workforce.
Org: University of California San Francisco, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Dana-Farber/Brigham and Women's Cancer Center, San Francisco VA Medical Center, University of Florida Health Shands Hospital,
Abstract
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.
Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Sutter Health, Intermountain Healthcare, Mayo Clinic,
Abstract
Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.
Org: The Ohio State University - James Cancer Hospital, Columbus, OH, Alliance NCTN Foundation, Chicago, IL, University of Colorado Denver Anschutz Medical Center,
Abstract
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
Org: University of California Los Angeles Medical Center, Mayo Clinic, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Vanadro LLC, University of Southern California Marshall School of Business,
Abstract
Impact of a web-based decision aid on socioeconomically disadvantaged patients’ engagement in decision making (Alliance A231701CD).
Org: Bay Area Tumor Institute, Mayo Clinic, Carle Cancer Center, Alliance for Clinical Trials in Oncology,
Abstract
A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).
Org: Mayo Clinic, Rochester Regional Health System, MN, Jacksonville, Flare Therapeutics,
Abstract
Artificial intelligence–derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer (NCCTG N0147; Alliance).
Org: Mayo Clinic, Lunit Inc., Roche Diagnostics, Department of Quantitative Science Research, Mayo Clinic College of Medicine,
Abstract
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
Org: Memorial Sloan Kettering Cancer Center, University of Chicago, Mayo Clinic, Massachusetts General Hospital, Seres Therapeutics,
Abstract
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.
Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, Miami Neuroscience Institute, Mayo Clinic, University of California Irvine,
Abstract
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.
Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,
Abstract
CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Mayo Clinic, Winship Cancer Institute of Emory University,
Abstract
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
Org: Sorbonne University and Saint-Antoine Hospital, Mayo Clinic, Monash University School of Public Health and Preventive Medicine, Cardiff University School of Medicine, University of Pisa, Pisa, Italy,
Abstract
Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
Org: University of California San Francisco, Quantum Leap Healthcare Collaborative, UCSF Breast Science Advocacy Core, Mayo Clinic, City of Hope National Medical Center,
Abstract
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
Org: Mayo Clinic, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Alabama-Birmingham,
Abstract
RET testing and treatment patterns among aNSCLC patients in US clinical practice.
Org: Genentech, University of Washington and Fred Hutchinson Cancer Research Centre, Mayo Clinic,
Abstract
A first-in-human pharmacodynamic evaluation of dual polyamine depletion for patients with high-grade gliomas.
Org: Mayo Clinic, Rochester, MN,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
Associations between early tumor shrinkage (ETS)/depth of response (DpR) and overall and post-progression survivals (OS/PPS) from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Org: National Cancer Center Hospital East, Kashiwa, Japan, Shizuoka Cancer Center, Nagaizumi, Japan, Kyushu University, University of Nantes Medical School, University Medical Center Utrecht,
Abstract
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
Org: Guardant Health, Inc., Mayo Clinic Florida, Mayo Clinic, Emory University, Atlanta, GA, USA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
Org: Mayo Clinic, Alliance Statistics and Data Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Neurology, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, Mayo Clinic Cancer Center,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.
Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Abstract
Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.
Org: Mayo Clinic Arizona, Phoenix, AZ, Caris Life Sciences, Irving, TX, Mayo Clinic, Department of Medicine, Duke University Medical Center, Caris MPI,
Abstract
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.
Org: Institut Curie, Saint Cloud, France, ICO Institut de Cancerologie de l'Ouest, Centre Léon Bérard, CEPCM Assistance Publique des Hôpitaux de Marseille, Mayo Clinic,
Abstract
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
Org: Cleveland Clinic Taussig Cancer Instititute, Guy’s and St Thomas’ NHS Foundation Trust, Hopital Saint-Louis, Wake Forest University School of Medicine, AOU Careggi,
Abstract
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.
Org: Dana-Farber Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, University Hospital and University of Zurich,
Abstract
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
Org: Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Emory University Winship Cancer Institute,
Abstract
Intra-operative desorption-electrospray ionization mass-spectrometry for real-time diagnosis, margin assessment, and maximization of brain cancer resection.
Org: Mayo Clinic Florida, Washington University School of Medicine in St Louis, Mayo Clinic, Purdue University,
Abstract
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Org: University of California San Diego Medical Center, La Jolla, CA, Wake Forest University School of Medicine, University of California San Francisco, University of Rochester Medical Center Department of Medical Oncology, University of Alabama at Birmingham Department of Hematology, Birmingham, AL,
Abstract
OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.
Org: Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute, Emory University School of Medicine, Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of WSD0922-Fu: Initial report from dose escalation cohort.
Org: Mayo Clinic, Rochester, MN, Jacksonville, FL, Phoenix, AZ, Wayshine Biopharm,
Abstract
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
Org: Cleveland Clinic Taussig Cancer Instititute, Beth Israel Deaconess Medical Center, Mayo Clinic, Replimune,
Abstract
Sequential monitoring of tumor macrophage fusion cells in the circulation of metastatic breast cancer and their prognostic value.
Org: Creatv MicroTech, Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Fox Chase Cancer Center, Greenebaum Comprehensive Cancer Center, Mayo Clinic,
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.
Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.
Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).
Org: BeiGene (USA) Co., Ltd., BeiGene (Shanghai) Co., Ltd., Sarah Cannon Research Institute/Tennessee Oncology, Monash Heath and Faculty of Medicine, Nursing and Health Sciences, Mayo Clinic,
Abstract
Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas.
Org: Mayo Clinic College of Medicine, Mayo Clinic, Roche Diagnostics, Department of Quantitative Science Research,
Abstract
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.
Org: Foundation Medicine, Inc., Cambridge, MA, Mayo Clinic, Foundation Medicine Inc, Morrisville, NC,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Org: Shizuoka Cancer Center, Nagaizumi, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Kyushu University, University of Nantes Medical School Nantes, University Medical Center Utrecht,
Abstract
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Comparison of synchronous neoplasms at colonoscopic diagnosis of early-onset versus average-onset colorectal cancer.
Org: Mayo Clinic, Rochester Regional Health System, MN,
Abstract
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
Org: Mayo Clinic, Division of Biomedical Statistics and Informatics, Mayo Clinic Florida, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Quantitative Science Research,
Abstract
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
Org: Bristol Myers Squibb, Mayo Clinic, Charite Universitats Medizin, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Roswell Park Comprehensive Cancer Center,
Abstract
Correlation of single-cell cytokine secretion with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with capecitabine (C), bevacizumab (B), ± atezolizumab (A).
Org: Duke University Medical Center, Mayo Clinic, Alliance Statistics and Data Management Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Impact of imaging frequency on progression free survival in Alliance clinical trials enrolling patients with untreated follicular lymphoma.
Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Emory University, Atlanta, GA, USA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Vermont Cancer Center,
Abstract
Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
Org: Mayo Clinic, Wills Eye Hospital, Oncolytics Biotech, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, University of Surrey,
Abstract
Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic, Alliance Statistics and Data Management Center, Vyriad,
Abstract
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent.
Org: Mayo Clinic, Sarah Cannon Transplant and Cellular Therapy Program, Genentech, F. Hoffmann-La Roche Ltd,
Abstract
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.
Org: National Cancer Institute/National Institutes of Health, Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, Lehigh Valley Health Network,
Abstract
Surgical care and outcomes in older patients with cancer through implementation of a pre-surgical toolkit (OPTI-Surg): Interim results of a phase III cluster randomized trial (Alliance A231601CD).
Org: MD Anderson Cancer Center, Alliance Statistics and Data Management Center, Mayo Clinic, American College of Surgeons, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.
Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Abstract
A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).
Org: ImmunoGen, University of Texas MD Anderson Cancer Center, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) IRCCS, Meldola, Italy, Roswell Park Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center,
Abstract
Trends in new and persistent opioid use in older adults with cancer.
Org: Yale School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New Haven, CT, Cancer Outcomes, Public Policy and Effectiveness Research Center, Public Policy and Effectiveness Research (COPPER) Center,
Abstract
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory and early relapsing diffuse large B-cell lymphoma (DLBCL).
Org: Mayo Clinic, Department of Quantitative Health Sciences, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Health Sciences Research, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).
Org: MD Anderson Cancer Center, Bristol Myers Squibb, Evidera, Inc, Seràgnoli Institute of Hematology, Winship Cancer Center of Emory University,
Abstract
An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab therapy in patients with locally advanced unresectable or metastatic hepatocellular carcinoma.
Org: Mayo Clinic, Scottsdale, AZ, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Baltimore, MD,
Abstract
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).
Org: Alliance Statistics and Data Management Center, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey, Dana-Farber Cancer Institute,
Abstract
Impact of best practice advisory on genetic counseling referral patterns for patients with endometrial cancer.
Org: University of Kentucky Medical Center, Department of Information Technology, University of Kentucky Chandler Medical Center, University of Kentucky College of Medicine, University of Kentucky Markey Cancer Center,
Abstract
Genomic landscapes of early-onset versus average-onset colorectal cancer populations.
Org: Mayo Clinic, Department of Quantitative Science Research, Vanderbilt-Ingram Cancer Center, University of Colorado Cancer Center, Tempus Labs, Inc.,
Abstract
Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.
Org: Legorreta Cancer Center, Brown University - Lifespan Cancer Institute, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Highlands Oncology,
Abstract
Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.
Org: Mayo Clinic, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,
Abstract
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Brigham and Women's Hospital/Massachusetts General Hospital, Princess Margaret Cancer Centre, Stanford Cancer Institute, Mayo Clinic,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.
Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,
Abstract
Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Org: Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, University of Washington, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Org: University of Pennsylvania, NYU Langone Medical Center, Vanderbilt University Medical Center, University of Chicago, Division of Pulmonary and Critical Medicine, Department of Medicine, Mayo Clinic,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Clinical characteristics, markers of adverse prognosis, and predictors of development of extramedullary multiple myeloma.
Org: Mayo Clinic, Mayo Clinic (Rochester, MN), Mayo Clinic Department of Pediatric and Adolescent Medicine, Division of Hematology, Mayo Clinic, Rochester, MN,
Abstract
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.
Org: Caris Life Sciences, Irving, TX, West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Mayo Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,
Abstract
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic College of Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA,
Abstract
Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).
Org: Bristol Myers Squibb, Princeton Health, Lille University Hospital, Lille, France, Mayo Clinic,
Abstract
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.
Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
Factors associated with myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Org: Bristol Myers Squibb, Mayo Clinic,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Org: Washington University School of Medicine in St Louis, Stanford Cancer Center, Centre Léon Bérard, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Ventriculoperitoneal shunt and performance status as prognostic factors of overall survival in a retrospective cohort of 78 adult patients with medulloblastoma.
Org: Hospital de Oncología, Centro Medico Nacional SXXI, Hospital de Oncologia Centro Medico Nacional Siglo XXI, CMN SXXI, Instituto Mexicano del Seguro Social,
Abstract
A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).
Org: Mayo Clinic, Division of Clinical Trials and Biostatistics, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Laboratory and Oncology, Mayo Clinic, Rochester, MN, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN,
Abstract
Disparity in regional recruitment across global cancer trials: A meta-analysis.
Org: Creighton University School of Medicine Phoenix Regional Campus, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Fatima Jinnah Medical University, University of Arizona,
Abstract
Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.
Org: University of Michigan, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic, Exact Sciences Corporation,
Abstract
Effect of DUAL pharmacological blockade of AURKA and PD-L1 pathways on plasticity and metastasis for triple negative breast cancer.
Org: Mayo Clinic, Rochester Regional Health System, MN,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Immune checkpoint inhibition in locally advanced rectal adenocarcinoma at Mayo Clinic.
Org: Mayo Clinic, Jacksonville, FL,
Abstract
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.
Org: Ann & Robert H. Lurie Children's Hospital, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Division of Pediatric Surgery, Medical College of Wisconsin, Department of Surgery, St. Jude Children's Research Hospital, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital,
Abstract
Rose geranium in sesame oil nasal spray to improve symptoms of nasal vestibulitis: A phase III double blinded randomized controlled trial.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Essentia Health,
Abstract
Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.
Org: Mayo Clinic in Arizona, Phoenix Tissue Repair, Azidus Brasil, Mayo Clinic Arizona, Phoenix, AZ, Scottsdale,
Abstract
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
Org: Mayo Clinic, Alliance Statistics and Data Management Center, Mayo Clinic Arizona, Phoenix, AZ, University of Pittsburgh Medical Center, Johns Hopkins Medicine,
Abstract
Outcomes of patients with multiple myeloma refractory to different administration schedules of bortezomib.
Org: Mayo Clinic,
Abstract
Genomic biomarker for the top risk factor of gallbladder cancer, cholelithiasis, in a Latinx population.
Org: Mayo Clinic, Scottsdale, AZ,
Abstract
Sexual orientation and gender identity data collection among NCI community oncology research program (NCORP) practices: A 5-year landscape update.
Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Wake Forest University School of Medicine, University of Wisconsin School of Medicine and Public Health, University of Rochester Medical Center,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.
Org: Mayo Clinic, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Clinical Trials and Biostatistics,
Abstract
Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.
Org: University of Michigan, Ann Arbor, Millennium Pharmaceuticals, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic,
Abstract
Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.
Org: Mayo Clinic, Beth Israel Deaconess Medical Center, Harvard Medical School, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute,
Abstract
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.
Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, NCI, Nihon Medi-Physics, National Cancer Institute, Vilnius, Lithuania, Institute for Clinical and Translational Research, Baylor College of Medicine,
Abstract
Source of funding and enrollment disparity in cancer clinical trials.
Org: Mayo Clinic, Nishtar Medical University Multan Pakistan, Medical University of South Carolina Hollings Cancer Center, Dow Medical College, Karachi, Pakistan, King Edward Medical University,
Abstract
Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer.
Org: American Cancer Society, Atlanta Cancer Care, Galderma R&D, Emory University School of Medicine, Roswell Park Comprehensive Cancer Center,
Abstract
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.
Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, The Ohio State University - James Cancer Hospital, Ohio State University College of Medicine, The Ohio State University Medical Center,
Abstract
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.
Org: OncoHost LTD, Heidelberg University Hospital, Heidelberg, Germany, Roswell Park Cancer Institute, Sheba Medical Center, Or-Yeuda, Rambam Health Care,
Abstract
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center, University of North Carolina at Chapel Hill, Mayo Clinic, Netherlands Cancer Institute,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.
Org: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Margaret Cancer Centre,
Abstract
Correlation of micronuclei formation in circulating stromal cells with their PD-L1 expression and predicts for poorer clinical outcomes in metastatic breast cancer.
Org: Creatv MicroTech, Inc., Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Fox Chase Cancer Center, Mayo Clinic, Greenebaum Comprehensive Cancer Center,
Abstract
A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients—A nationwide cross-sectional study.
Org: Emilio Aguinaldo College, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Medicine and Pharmacy at Ho Chi Minh City, Mayo Clinic, KIMS Hospital,
Abstract
Using EHR data and machine learning approach to facilitate the identification of patients with lung cancer from a pan-cancer cohort.
Org: Mayo Clinic, University of Bergen, Johns Hopkins University Bloomberg School of Public Health, University of North Carolina at Chapel Hill,
Abstract
A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Org: Memorial Sloan Kettering Cancer Center, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group, Mayo Clinic,
Abstract
Incidence of additional primary malignancies in patients with malignant peritoneal mesothelioma.
Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts.
Org: Invitae, Mayo Clinic, Mayo Clinic Cancer Center Scottsdale, Mayo Clinic in Arizona, Division of Gastroenterology and Hepatology, Mayo Clinic,
Abstract
Role of ketogenic diet in the management of cancer: A systematic review.
Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, KIMS Hospital, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Emilio Aguinaldo College, Sir Seewoosagur Ramgoolam Medical College,
Abstract
Evaluating social vulnerability impact on care and prognosis of head & neck-nervous system cancers in the US.
Org: Louisiana State University Health and Sciences - School of Medicine, Northwestern University - Feinberg School of Medicine, Department of Otolaryngology-Head and Neck Surgery, Pediatric Thyroid Tumor Program, Pediatric Head and Neck Tumor Program,
Abstract
Evaluation of local control strategies on patterns of treatment failure in patients with localized Ewing sarcoma treated on AEWS1031: A report from the Children’s Oncology Group.
Org: Mayo Clinic Arizona, Phoenix, AZ, Moffitt Cancer Center, Children's Oncology Group, Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville,
Abstract
Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer.
Org: Mayo Clinic, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, City of Hope National Medical Center, Daiichi Sankyo Inc., Daiichi Sankyo Co. Ltd.,
Abstract
Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India.
Org: BALCO Medical Center, Ernakulam Medical Centre and MOSC Medical College, MVR Cancer Center and Research Institute, Amrita Institute of Medical Sciences, Mediclinic City Hospital,
Abstract
Single cell multiomic profiling of high-grade serous carcinoma.
Org: Mayo Clinic, Mayo Clinic School of Medicine,
Abstract
Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma.
Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
Survival in patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Molecular and clinical characteristics of patients with KRAS mutated pancreatic ductal adenocarcinoma.
Org: Mayo Clinic-Rochester, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, UH Seidman Cancer Center, Case Western Reserve University School of Medicine,
Abstract
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.
Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,
Abstract
Investigation of the prognostic significance of CD5, CD117, EZH2, POU2F3, MTAP and BAP1 in thymic carcinoma.
Org: Mayo Clinic, Department of Laboratory Medicine and Pathology, University of Washington, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Division of Thoracic Surgery, Brigham and Women's Hospital, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.
Org: Mayo Clinic, H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic Florida,
Abstract
Outcomes of peritoneal metastases in mismatch repair deficient (dMMR) cancers treated with immune checkpoint inhibitors and variables associated with response.
Org: Mayo Clinic Florida, Mayo Clinic, Mayo Clinic Jacksonville, Rochester Regional Health System, MN,
Abstract
Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies.
Org: Vyriad, Mayo Clinic, Mayo Clinic, Division of Hematology, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Alliance Statistics and Data Management Center,
Abstract
Return to work in breast cancer patients with and without pre-diagnosis psychological distress.
Org: Mayo Clinic, Jacksonville, Flare Therapeutics, Rochester Regional Health System, MN,
Abstract
Predictors of survival outcomes in patients with MECOM EVI1 rearrangement aberrations in AML or MDS.
Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Mayo Clinic Jacksonville, Division of Hematopathology, Mayo Clinic, Rochester, MN,
Abstract
Circulating ether lipids in prostate cancer.
Org: Chris O'Brien Lifehouse, Garvan Institute of Medical Research, Baker Institute, Baker Heart and Diabetes Institute, St Vincent's Hospital,
Abstract
A multi-component educational intervention for oncologists to improve tobacco cessation treatment among patients with cancer who smoke.
Org: Mayo Clinic, Rochester, MN,
Abstract
Translational development of BAFF-R-specific chimeric antigen receptor T-cell therapy targeting B-cell lymphoid malignancies.
Org: Mayo Clinic Florida, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic,
Abstract
Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience.
Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Tolerability of lutetium-177–PSMA-617 in men with prostate cancer and baseline cytopenia.
Org: Mayo Clinic, Rochester, MN, Mayo Clinic - Rochester, MN,
Abstract
Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR.
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Mayo Clinic, Charité Universitätsmedizin Berlin, Stanford University Medical Center, Stanford, CA, Stanford University School of Medicine,
Abstract
Anthracycline-related cardiotoxicity among patients with lymphoma: Systematic review and meta-analysis.
Org: Mayo Clinic, Rochester Regional Health System, MN, Mayo Clinic-Rochester, City of Hope National Medical Center,
Abstract
Incidence of other multiple primary malignancies in patients with adrenocortical carcinoma.
Org: Mayo Clinic, Jacksonville, FL, Mayo Clinic Florida,
Abstract
Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.
Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL).
Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Alexandra Hospital and University of Queensland, Mayo Clinic,
Abstract
Systematic review determining the characteristics of primary bone lymphoma.
Org: University of Texas Health Science Center at San Antonio, San Antonio, TX, UT Health San Antonio, MD Anderson Cancer Center, Mayo Clinic, Rochester, MN,
Abstract
Patient-provider communication factors associated with mt-sDNA screening for colorectal cancer.
Org: Exact Sciences Corporation, Mayo Clinic, RTI International,
Abstract
Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: A systematic review and meta-analysis.
Org: A.C. Camargo Cancer Center, Faculdade de Medicina de Barbacena FAME-FUNJOB, Universidade Federal do Rio Grande do Norte, Federal University of Rio de Janeiro, Mayo Clinic,
Abstract
Effect of immunotherapy cessation without disease progression on outcomes in patients with metastatic non-small cell lung cancer.
Org: Mayo Clinic Florida, Jacksonville, Mayo Clinic,
Abstract
Survival trends among patients with mesothelioma: Impact of initial therapy at academic centers.
Org: Mayo Clinic, Jacksonville, FL,
Abstract
Risk and protective factors for dementia in cancer survivors vary by cancer type.
Org: Mayo Clinic, Rochester, MN,
Abstract
An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors.
Org: McGill University Health Center, The Second Affiliated Hospital Of Nanchang University, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center,
Abstract
Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience.
Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
AUTO-REACTIVE B CELLS ESCAPE PERIPHERAL TOLERANCE CHECKPOINTS IN PATIENTS WITH PR3-ANCA ASSOCIATED VASCULITIS
Org: Mayo Clinic, CHRU de Nancy, University College London, Centre for Rheumatology, Division of Medicine, London, United Kingdom,
Abstract
Ankylosing spondylitis and rheumatoid arthritis hospitalisation trends in the us: data from national inpatient sample
Org: Mayo Clinic, Reading Hospital and Medical Center,
Abstract
ARE THERE SEX DIFFERENCES IN RISK AND OUTCOMES OF STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS? A POPULATION-BASED RETROSPECTIVE COHORT STUDY
Org: Mayo Clinic,
Abstract
ASSOCIATION OF PROTEINASE 3 GENE (PRTN3) Val119Ile POLYMORPHISM (SNP rs351111) WITH RISK OF RELAPSE AMONG HOMOZYGOUS PATIENTS WITH PR3 ANCA-ASSOCIATED VASCULITIS
Org: Mayo Clinic, National Intitute of Health, Genentech Inc., University of Groningen, Cleveland Clinic Taussig Cancer Instititute,
Abstract
ASSOCIATIONS OF 31 NOVEL COPA NON-SYNONYMOUS VARIANTS WITH AUTOIMMUNE AND INFLAMMATORY CLINICAL PHENOTYPES AMONG 160,365 INDIVIDUALS: DEFINING A COPA SPECTRUM DISORDER
Org: Brigham and Women’s Hospital, Mayo Clinic, Université de Paris, Boston Children’s Hospital, Massachusetts General Hospital,
Abstract
B CELLS IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL PNEUMONIA AND IDIOPATHIC INTERSTITIAL PNEUMONIAS
Org: Mayo Clinic,
Clinical trial
The Efficacy of Intravenous Hydroxocobalamin Versus Methylene Blue as Treatment for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded From Peripheral Blood in Patients With Relapsed and Resistant Ovarian Cancer
Status: Not yet recruiting, Estimated PCD: 2028-09-01